Dennis H. Langer, MD, JD
Dr. Langer has served as a director of Quoin Inc. since 2019 and as a director of Quoin Ltd. since October 28, 2021. After graduating from Georgetown School of Medicine and Harvard Law School, Dr. Langer spent over 35 years in the pharmaceutical industry at Eli Lilly, Abbott, Searle, GSK and as President at Dr. Reddy’s Pharmaceuticals. He has also served as Chief Executive Officer at Neose Technologies, Inc. Dr. Langer has served as director at a number of companies including Sirna Therapeutics (acquired by Merck), Ception Therapeutics (acquired by Cephalon), Transkaryotic Therapies (acquired by Shire), Pharmacopeia (acquired by Ligand), Cytogen (acquired by EUSA Pharma), Brooklyn ImmunoTherapeutics, Inc. and Delcath Systems. Dr. Langer is currently a Director at Myriad Genetics, Dicerna Pharmaceuticals and Pernix Therapeutics. He is a Clinical Psychiatry Professor at Georgetown and serves on the Dean’s Advisory Board of Harvard Law School. He received an M.D. from Georgetown University School of Medicine, a J.D. from Harvard Law School, and a B.A. in Biology from Columbia University.